• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本卵巢癌患者的家族史和 BRCA1/BRCA2 状态,以及一例 BRCA1 突变病例中的隐匿性癌症。

Family history and BRCA1/BRCA2 status among Japanese ovarian cancer patients and occult cancer in a BRCA1 mutant case.

机构信息

*Department of Obstetrics and Gynecology, School of Medicine, Keio University, 35 Shinanomachi, Shinjyuku-ku, Tokyo 160-8582, Japan.

出版信息

Jpn J Clin Oncol. 2014 Jan;44(1):49-56. doi: 10.1093/jjco/hyt171. Epub 2013 Nov 11.

DOI:10.1093/jjco/hyt171
PMID:24218521
Abstract

BACKGROUND

This study aimed to examine family history among Japanese ovarian cancer patients and to investigate the TP53 status of fallopian tube epithelial and ovarian cancer cells in a Japanese BRCA1 mutant case that may be associated with the transformed state in hereditary ovarian cancer.

METHODS

One hundred and two primary ovarian cancer patients were retrospectively evaluated in this cross-sectional study. The family history of cancer was determined in probands. In a BRCA1 mutant case, p53 immunostaining and direct sequencing, followed by laser-capture microdissection, were performed for the fallopian tube, considered the origin of ovarian cancer.

RESULTS

Nine of 102 (8.8%) families were regarded as having hereditary breast-ovarian cancer syndrome, two families (2.0%) were diagnosed with Lynch syndrome and six patients harbored BRCA1 or BRCA2 mutations. One case underwent risk-reductive salpingo-oophorectomy as a BRCA1 mutant carrier was retrospectively diagnosed as occult cancer. Common TP53 mutations were detected in cancer and fallopian tube epithelial cells in the case.

CONCLUSIONS

Here, we integrate family cancer history and histology in ovarian cancer cases as well as TP53 status in a BRCA1 mutant case into a discussion regarding carcinogenesis in a Japanese population. The TP53 status for the BRCA1 mutant case examined here supports the recently proposed theory that ovarian cancer develops because of BRCA1 or BRCA2 inactivation and/or TP53 mutations.

摘要

背景

本研究旨在研究日本卵巢癌患者的家族史,并调查可能与遗传性卵巢癌转化状态相关的 BRCA1 突变病例中输卵管上皮和卵巢癌细胞的 TP53 状态。

方法

在这项回顾性的病例研究中,我们对 102 名原发性卵巢癌患者进行了评估。在先证者中确定了癌症的家族史。在 BRCA1 突变病例中,进行了 p53 免疫组化和直接测序,随后进行了激光捕获微切割,用于研究输卵管,这被认为是卵巢癌的起源。

结果

9 个家族(8.8%)被认为患有遗传性乳腺癌-卵巢癌综合征,2 个家族(2.0%)被诊断为林奇综合征,6 名患者携带 BRCA1 或 BRCA2 突变。一个病例作为 BRCA1 突变携带者进行了风险降低的输卵管卵巢切除术,该病例被回顾性诊断为隐匿性癌症。在该病例中,在癌症和输卵管上皮细胞中检测到常见的 TP53 突变。

结论

在这里,我们将卵巢癌病例中的家族癌症史和组织学以及 BRCA1 突变病例中的 TP53 状态综合起来,讨论了日本人群中的癌症发生机制。我们研究的 BRCA1 突变病例的 TP53 状态支持了最近提出的理论,即卵巢癌的发生是由于 BRCA1 或 BRCA2 失活和/或 TP53 突变。

相似文献

1
Family history and BRCA1/BRCA2 status among Japanese ovarian cancer patients and occult cancer in a BRCA1 mutant case.日本卵巢癌患者的家族史和 BRCA1/BRCA2 状态,以及一例 BRCA1 突变病例中的隐匿性癌症。
Jpn J Clin Oncol. 2014 Jan;44(1):49-56. doi: 10.1093/jjco/hyt171. Epub 2013 Nov 11.
2
Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.对BRCA1和BRCA2突变携带者进行降低风险的输卵管卵巢切除术所获得的卵巢和输卵管上皮中γ-H2AX和p53核表达水平的定量分析。
Int J Gynecol Pathol. 2014 May;33(3):309-16. doi: 10.1097/PGP.0b013e31829c673b.
3
Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.BRCA1 突变携带者行预防性输卵管卵巢切除术的经验及遗传性乳腺癌卵巢癌综合征预防性手术体系在日本的建立:我们未来的挑战。
Jpn J Clin Oncol. 2013 May;43(5):515-9. doi: 10.1093/jjco/hyt036. Epub 2013 Mar 13.
4
Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients.多民族亚洲卵巢癌患者队列中种系BRCA1和BRCA2突变的评估。
Gynecol Oncol. 2016 May;141(2):318-322. doi: 10.1016/j.ygyno.2015.11.001. Epub 2015 Nov 3.
5
Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome.遗传性乳腺癌和卵巢癌综合征中卵巢、输卵管和原发性腹膜癌淋巴结转移的危险因素。
Jpn J Clin Oncol. 2020 Dec 16;50(12):1380-1385. doi: 10.1093/jjco/hyaa124.
6
Risk-reducing salpingo-oophorectomy among Chinese women at increased risk of breast and ovarian cancer.降低风险的输卵管卵巢切除术在有较高乳腺癌和卵巢癌风险的中国女性中。
J Ovarian Res. 2023 Jun 29;16(1):125. doi: 10.1186/s13048-023-01222-1.
7
Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.早期输卵管切除术(输卵管切除)联合延迟卵巢切除术以改善生活质量,作为BRCA1/2突变携带者降低风险的输卵管卵巢切除术的替代方案(TUBA研究):一项前瞻性非随机多中心研究。
BMC Cancer. 2015 Aug 19;15:593. doi: 10.1186/s12885-015-1597-y.
8
Retrospective evaluation of risk-reducing salpingo-oophorectomy for BRCA1/2 pathogenic variant carriers among a cohort study in a single institution.回顾性评估单中心队列研究中 BRCA1/2 致病性变异携带者的预防性输卵管卵巢切除术。
Jpn J Clin Oncol. 2021 Feb 8;51(2):213-217. doi: 10.1093/jjco/hyaa173.
9
Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report.BRCA1/2 相关乳腺癌化疗后行输卵管卵巢切除术时偶然发现隐匿性妇科癌行辅助化疗和知情显微镜检查的价值:病例报告。
Jpn J Clin Oncol. 2021 Mar 3;51(3):492-497. doi: 10.1093/jjco/hyaa239.
10
TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol.输卵管切除术联合延迟卵巢切除术作为高风险女性降低风险的输卵管卵巢切除术替代方案,以评估预防的安全性:TUBA-WISP II 研究方案。
Int J Gynecol Cancer. 2023 Jun 5;33(6):982-987. doi: 10.1136/ijgc-2023-004377.

引用本文的文献

1
Using species richness calculations to model the global profile of unsampled pathogenic variants: Examples from BRCA1 and BRCA2.使用物种丰富度计算来模拟全球未采样的致病性变异体分布模式:BRCA1 和 BRCA2 的实例。
PLoS One. 2023 Feb 8;18(2):e0278010. doi: 10.1371/journal.pone.0278010. eCollection 2023.
2
variants in p53 signatures and the clonality of STICs in RRSO samples.RRSO样本中p53特征的变异及浆液性输卵管原位癌的克隆性
J Gynecol Oncol. 2022 Jul;33(4):e50. doi: 10.3802/jgo.2022.33.e50. Epub 2022 Mar 21.
3
TP53 mutations in epithelial ovarian cancer.
上皮性卵巢癌中的TP53突变
Transl Cancer Res. 2016 Dec;5(6):650-663. doi: 10.21037/tcr.2016.08.40.
4
Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer.在未经选择的日本卵巢癌患者中,通过多基因测序检测到的致病种系变异的患病率。
Oncotarget. 2017 Nov 28;8(68):112258-112267. doi: 10.18632/oncotarget.22733. eCollection 2017 Dec 22.
5
Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.台湾卵巢癌患者中BRCA1/2种系和体细胞突变的患病率及临床意义
Oncotarget. 2016 Dec 20;7(51):85529-85541. doi: 10.18632/oncotarget.13456.